Objectives and background: Recent guidelines recommend insulin-like growth factor (IGF-1), random growth hormone (GH) and nadir GH on an oral glucose tolerance test (OGTT) for assessment of acromegaly. At this Regional Centre, the 24-hour GH profile has also been used.
| INTRODUCTION
The Endocrine Society guidelines (2014) advocate the use of insulinlike growth factor (IGF-1), random growth hormone (GH) and nadir GH after oral glucose tolerance test (OGTT) for assessment of acromegaly. Insulin-like growth factor-1 is the most sensitive and specific test for the diagnosis of acromegaly. However, the IGF-1 recommendation in the guideline is predicated on the clinician having a knowledge of the specific assay used and its limitations including interassay variability. 2, 3 It is also advised that the same assay be used in a given patient over time. In clinical practice, preservation of the same assay has become increasingly difficult with laboratories undergoing more frequent tendering cycles.
In our regional centre, the IGF-1 assay available to us has changed over time and we have been unable to maintain multiple assays so as to keep the same assay true to a given patient. In these circumstances, the GH profile provided additional information albeit with a changing GH assay also over time.
Historically, we have used a 24-hour profile using 2-hourly GH measurements (13 results) rather than the usual 8-hour GH day profiles (5 results). These measurements began in a research setting over 30 years ago and became routine practice in our Regional Centre.
The relationship between serum GH and IGF-1 is linear below GH levels of 20 μg/L but above this level circulating IGF-1 levels plateau. [4] [5] [6] [7] This effect has led to some concern that postoperative IGF-1 levels in large and metabolically active tumours may not adequately reflect partial therapeutic success. It has been postulated that GH profiling may provide additional information in these patients.
There is increasing recognition that in a minority of patients, GH
and IGF-1 levels are discordant either in an intermittent or persistent way. 8 This may be exacerbated by surgery, external pituitary irradiation or medical treatment. The significance of recurrence, morbidity and mortality is unclear as are the best prognostic markers in this group. Multiple daytime GH measurements to establish either an area under the curve or a mean has been suggested by some authors for patients with either an elevated IGF-1 or normal OGTT or vice versa.
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We performed a retrospective analysis to examine the relationship between 24-hour GH profile results and IGF-1, random GH, nadir GH after OGTT and GH day profiles across treatment.
| MATERIALS AND METHODS
We evaluated 57 GH profiles from 34 patients, 25 of whom were new diagnoses, between April 2008 and December 2012 when both GH and IGF-1 assays remained unchanged. In 20 of these new diagnoses, profiles were available both preoperatively and 3 month postoperatively. Three of these patients also had an early postoperative 24-hour GH profile. Samples were drawn every 2 hour from 0800 to 0800 (13 time points) and matched with OGTT and IGF-1. GH was measured using Immulite 2000 solid-phase, 2-site chemiluminescent immunometric assay (CVs < 10% Patient characteristics are set out in Table 1 . All were enrolled in the national UK Acromegaly database with appropriate consents.
Failure to suppress GH secretion to <1 ng/mL following 75 g
OGTT was considered diagnostic of acromegaly.
| RESULTS
The correlation between the mean 13-and 5-point (0800-1600)
profile was strong (r = .99, P < .01 Figure 1 ). Of the subgroup of 25 patients with pre-and/or postoperative evaluation, mean 13-and 5-point profiles were similar to the group as a whole (r = .99 and .98, respectively, P < .01). A similar relationship was seen between the 13-point profile and nadir GH on OGTT (r = .99 P < .01 Figure 2 ).
Correlation between the mean 13-point profile and 0800 GH was strong (r = .90, P < .01 Figure 3 ). The correlation between mean 13-point profile and IGF-1 was moderate (r = .32, P < .05 Figure 4 ).
Preoperatively, there was full concordance between 0800 GH, IGF-1 and GH profiles, that is all were above their respective diagnostic thresholds/normal range.
The value of the 1400 sample during the 24-hour GH profile was also evaluated. Across the whole cohort, 50 of 57 profiles demonstrated concordant GH measures at 0800 and 1400. In 6 of the 7 discordant profiles, the 0800 sample was concordant with the IGF-1. F I G U R E 1 Thirteen-point mean growth hormone (GH) vs 5-point mean GH for whole cohort low GH (<1 μg/L) at 0800 and 1400 hour. There was discordance in 4 patients. Of these, 2 had a high 0800 GH, low 1400 GH with high IGF-1. One had low 0800 GH, high 1400 GH with high IGF-1 and one had low 0800 GH, high 1400 GH with normal IGF-1. Overall, therefore, the 0800 GH was concordant with the IGF-1 in 3 of the 4 patients.
Six patients had discordant results postoperatively with normal 0800 GH but elevated IGF-1. Their biochemical profiles are illustrated in Table 2 In the 5 patients with very high 0800 GH (≥20 μg/L) preoperatively, reductions in GH postoperatively were considerable (88%-99%) and in 1 patient mean GH was <1 μg/L. In all 5 patients, IGF-1 was not normalized being modestly reduced (34%-64%) and in 1 patient elevated by 33%. Persistent disease was deemed to be present in all 5 patients in this group. A 13-point profile did not add to the clinical management of these patients. Their profiles are summarized in Table 3 .
We found that in the 16 patients with very high IGF-1 levels preoperatively (>100 nmol/L), it took longer than 3 months to plateau postoperatively. In 11 of these, repeat sampling 6-12 months later showed further reduction without extra treatment. GH between these 2 ranges (ie, 2.5-5.0 μg/L), the predictive value was much less and as such the 0800 GH was not predictive of GH status as measured by OGTT, 5-point or 13-point profiles.
| DISCUSSION
The 13-point GH profile as an extension of the 5-point profile was adopted in a research setting in our Centre in the 1990s. [15] [16] [17] [18] [19] We are unaware of any other groups using the 13-point 24-hour GH profile in clinical practice. Publications using this assessment initially explored the dose response of octreotide in resistant acromegaly. With the development of long-acting analogues, the 13-point GH mean was also used to demonstrate its comparable efficacy to subcutaneous octreotide. 17 The latter study demonstrated a significant correlation between mean 24-hour GH levels and serum IGF-1 (r = .39, P = .03), similar to the current study (r = .32, P < .02), although the assays used previously were different (serum GH double-monoclonal antibody technique) (Delfia) and serum IGF-1 was measured by RIA (Nichols CA).
The literature on 24-hour GH profiling in acromegaly is sparse.
When profiling has been undertaken in research settings, this has typically been labour-intensive with GH measurements being drawn every 10-20 minutes. 4, 21 The recent study by Roelfsema et al 22 demonstrated that in patients with active acromegaly and those on SSA therapy, a shorter day curve correlated strongly with a 144-point 24-hour GH profile.
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F I G U R E 2 Thirteen-point mean growth hormone (GH) vs nadir GH on oral glucose tolerance test (OGTT) F I G U R E 3 Thirteen-point mean growth hormone (GH) vs 8am GH
F I G U R E 4 Thirteen-point mean growth hormone (GH) vs IGF-1
T A B L E 2 Discordant postoperative patients: normal 0800 GH (growth hormone) with high IGF-1 (insulin-like growth factor-1) T A B L E 3 High pre-operative 0800 GH (growth hormone) cohort Concern remains with regard to IGF-1 assay standardization.
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One study group studied all 23 centres participating in the UK National External Quality Assessment Service (NEQAS) for IGF-1 with a clinical scenario. 23 Each centre was asked to measure IGF-1, interpret the result and provide the source of their reference ranges.
A 50% variation was found in the upper limit of the reference ranges between centres using the same method. Overall, 30% of the IGF-1 results were against the diagnosis. The relationship between serum GH levels above 20 μg/L and IGF-1 plateaus. [4] [5] [6] [7] This effect has led to some concern that postop- The use of 5-point GH day curves has been advocated over random GH measures as it accommodates some degree of GH pulsatility in GH secretion. Day curves have also been suggested as a means for discriminating those patients with discordant GH and IGF-1 measurements postoperatively. 8, 9 More recent evidence however suggests that it is the basal GH secretion rather than peak/pulsatile secretion that determines the serum IGF-1. 28 In keeping with this, a recent meta-analysis of discordant IGF-1/GH studies in treated acromegaly demonstrated that using mean GH profiles produced the highest rates of discordance with IGF-1 compared to random GH and OGTT nadir GH.
For those patients in whom remission is not achieved and disease control is the aim, a number of authors have advocated GH levels of <2.5 μg/L as being associated with a normalization of the mortality risk and thus a therapeutic target. 25, 26, 30, 31 Where this is the case, it has been demonstrated that a single 0800 GH sample of <2.5 μg/L is strongly predictive of a similar result when assessed by OGTT or GH day curve. A similar relationship was reported for 0800 GH >5.0 μg/L whilst those in the range 2.5-5.0 μg/L warranted dynamic testing. 32 These patterns were also demonstrated in our cohort albeit with very small numbers.
Overall, there remains considerable challenge in the biochemical assessment of acromegaly following treatment where there is discordance between GH and IGF-1. In many cases, serial retesting over the following months will clarify disease control or relapse. Ambiguity persists with regard to the appropriate cut-offs for GH and similarly so for adjustment of IGF-1 for confounding variables. There is a need for further research into the natural history of patients with discordant biochemistry following treatment for acromegaly. Our discordant cases here are too few to draw any meaningful conclusions.
| CONCLUSIONS
Growth hormone profiling is not necessary for assessing the majority of patients with acromegaly if there is confidence in the local insulinlike growth factor-1 assay. When undertaken, a 5-point profile is adequate rather than a 13-point profile which would require an inpatient stay and does not appear to add value to the overall assessment.
